Science News: Late Breaking Trials

Scientific Sessions 2018

November 10–12

Chicago, Illinois

Please note that abstracts, presentations, and results are embargoed until time of presentation.

LBS.01 - Answers to Critical Questions in Cardiovascular Prevention

JoAnn E Manson | Harvard Medical School, Boston, MA

The VITamin D and OmegA-3 TriaL (VITAL): Principal Results for Vitamin D and Omega-3 Fatty Acid Supplementation in the Primary Prevention of Cardiovascular Disease and Cancer
JoAnn E Manson | Harvard Medical School, Boston, MA


Deepak L. Bhatt | Brigham and Women's Hospital, Boston, MA

The Primary Results of the REDUCE-IT Trial
Deepak L. Bhatt | Brigham and Women's Hospital, Boston, MA


Yasuyoshi Ouchi | Toranomon Hospital, Tokyo, Japan

Ezetimibe in Prevention of Cerebro- and Cardiovascular Events in Middle- to High-Risk, Elderly (75 Years Old or Over) Patients With Elevated LDL-Cholesterol: A Multicenter, Randomized, Controlled, Open-Label Trial
Yasuyoshi Ouchi | Toranomon Hospital, Tokyo, Japan


Deepak L. Bhatt | Brigham and Women's Hospital, Boston, MA

Cost-Effectiveness of Alirocumab Based on Evidence From a Large Multinational Outcome Trial: The ODYSSEY OUTCOMES Economics Study
Deepak L. Bhatt | Brigham and Women's Hospital, Boston, MA

LBS.02 - Novel Approaches to CV Prevention

Stephen D Wiviott | Brigham and Womens Hospital, Boston, MA

The Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial
Stephen D Wiviott | Brigham and Womens Hospital, Boston, MA


Paul M Ridker | Brigham Womens Hospital, Boston, MA

The Cardiovascular Inflammation Reduction Trial (CIRT): Low Dose Methotrexate for the Prevention of Atherosclerotic Events
Paul M Ridker | Brigham Womens Hospital, Boston, MA


Sotirios Tsimikas | University of California San Diego, La Jolla, CA

Safety and Efficacy of AKCEA-APO(a)-LRx to Lower Lipoprotein(a) Levels in Patients With Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial
Sotirios Tsimikas | University of California San Diego, La Jolla, CA


Dorairaj Prabhakaran | Center for Chronic Disease Control, New Delhi, India

Effectiveness of a Yoga-Based Cardiac Rehabilitation (yoga-care) Program: A Multi-Centre Randomised Controlled Trial of 4,014 Patients With Acute Myocardial Infarction From India
Dorairaj Prabhakaran | Center for Chronic Disease Control, New Delhi, India

LBS.03 - Harnessing Technology and Improving Systems for Global Health

Otavio Berwanger | Heart Hospital, Sao Paulo, Brazil

Effects of a Multifaceted Intervention to Narrow the Evidence-Based Gap in the Treatment of High Cardiovascular Risk Patients: The BRIDGE CV Prevention Cluster Randomized Trial
Otavio Berwanger | Heart Hospital, Sao Paulo, Brazil


M. Julia Machline Carrion | Heart Hospital, Sao Paulo, Brazil

An International Cluster Randomized Quality-Improvement Trial to Increase the Adherence to Evidence-Based Therapies for Acute Ischemic Stroke and Transient Ischemic Attack Patients - The Bridge Stroke Trial
M. Julia Machline Carrion | Heart Hospital, Sao Paulo, Brazil


Gregory Piazza | Brigham & Women's Hospital, Boston, MA

Alert-Based Computerized Decision Support to Increase Anticoagulation Prescription Prevents Stroke and Myocardial Infarction in High-Risk Hospitalized Patients With Atrial Fibrillation: A Randomized, Controlled Trial
Gregory Piazza | Brigham & Women's Hospital, Boston, MA


Jafna Layth Cox | QEII Health Sciences Center, Halifax, NS, Canada

Efficacy of Electronic Clinical Decision Support in Atrial Fibrillation: Results of the Integrated Management Program Advancing Community Treatment of Atrial Fibrillation (IMPACT-AF)
Jafna Layth Cox | QEII Health Sciences Center, Halifax, NS, Canada

  • RESULTS: An online, evidence-based computer decision support system did not significantly affect the number of patients experiencing the unplanned cardiovascular hospitalization and/or AF-related emergency room visit at 12 months.
  • Abstract for IMPACT-AF
  • Presentation Slides (PDF) for Cox

Dorairaj Prabhakaran | Center for Chronic Disease Control, New Delhi, India

Effectiveness of mHealth Based Decision Support System for Integrated Management of Chronic Conditions in Primary Care: The mWellcare Trial
Dorairaj Prabhakaran | Center for Chronic Disease Control, New Delhi, India

LBS.04 - Preserving Brain & Heart in Acute Care Cardiology

Per Nordberg | Karolinska Institute, Stockholm, Sweden

Pre-Hospital Resuscitation Intra-Arrest Cooling Effectiveness Survival Study - The Princess Trial
Per Nordberg | Karolinska Institute, Stockholm, Sweden


Koen Ameloot | Ziekenhuis Oost Limburg, Genk, Belgium

Early Goal-Directed Hemodynamic Optimization in Comatose Survivors After Out-of-Hospital Cardiac Arrest: The Neuroprotect Trial
Koen Ameloot | Ziekenhuis Oost Limburg, Genk, Belgium

  • RESULTS: A higher mean arterial pressure (MAP) in the ICU during the first 36 hours after cardiac arrest improved cerebral perfusion and oxygenation but did not decrease anoxic brain damage or improve functional outcome compared to the lower MAP target of 65mmHg.
  • Abstract for Neuroprotect
  • Presentation Slides (PDF) for Ameloot

Colin Berry | University of Glasgow, Scotland, United Kingdom

A Randomized, Double Blind, Placebo-Controlled, Parallel Group, Multicenter Clinical Trial of Low-Dose Adjunctive Alteplase During Primary PCI (T-TIME)
Colin Berry | University of Glasgow, Scotland, United Kingdom


Laurent Bonello | Aix Marseille University, Marseille, France

Optimal Timing of Intervention in Non St-Elevation Acute Coronary Syndromes Without Pretreatment
Laurent Bonello | Aix Marseille University, Marseille, France


Navin K Kapur | Tufts Medical Center, Hanover, MA

Mechanically Unloading the Left Ventricular and Delaying Reperfusion in Patients With Anterior ST-Segment Elevation Myocardial Infarction: The Door to Unload Pilot Trial
Navin K Kapur | Tufts Medical Center, Hanover, MA

LBS.05 - Hot News in HF

Eric J Velazquez | Yale University School of Medicine, New Haven, CT

Angiotensin Receptor-Neprilysin Inhibition in Patients Hospitalized With Acute Decompensated Heart Failure: Primary Results of the PIONEER-HF Randomized Controlled Trial
Eric J Velazquez | Yale University School of Medicine, New Haven, CT


Brian P Halliday |, Imperial College of London, London, United Kingdom

Withdrawal of Pharmacological Heart Failure Therapy in Recovered Dilated Cardiomyopathy - A Randomised Controlled Trial (TRED-HF)
Brian P Halliday |, Imperial College of London, London, United Kingdom


Barry H Greenberg | University of California, San Diego, San Diego, CA

Effects of Rivaroxaban on Thrombotic Events in Heart Failure Patients With Coronary Disease and Sinus Rhythm
Barry H Greenberg | University of California, San Diego, San Diego, CA


Subodh Verma | St Michael's Hospital, Toronto, ON, Canada

EMPA-HEART Cardiolink-6 Trial: A Randomized Trial Evaluating the Effect of Empagliflozin on Left Ventricular Structure, Function and Biomarkers in People With Type 2 Diabetes (T2D) and Coronary Heart Disease
Subodh Verma | St Michael's Hospital, Toronto, ON, Canada


Michael B Stokes | University of Adelaide, Royal Adelaide Hospital, Adelaide, Australia

Cardiac Remodeling Following Ligation of Arteriovenous Fistula in Stable Renal Transplant Recipients: A Randomised Controlled Study
Michael B Stokes | University of Adelaide, Royal Adelaide Hospital, Adelaide, Australia

LBS.06 - Late Breaking Science in Coronary Revascularization

Marco A Zenati | Veterans Affairs Boston Healthcare System and Harvard Medical School, Boston, MA

Endoscopic Vein Harvest for Coronary Bypass Surgery in a Randomized Multicenter Trial With Long-Term Follow-Up
Marco A Zenati | Veterans Affairs Boston Healthcare System and Harvard Medical School, Boston, MA


Valentin Fuster, Icahn School of Medicine at Mount Sinai, New York, NY

Long-Term Survival Following Multivessel Revascularization in Patients With Diabetes: The FREEDOM Follow-On Study
Valentin Fuster, Icahn School of Medicine at Mount Sinai, New York, NY


Heribert Schunkert |German Heart Center of Munich, Munich, Germany

TiCAB: A Randomized, Double-Blind Study of Ticagrelor versus Aspirin in Patients Undergoing Coronary Bypass Surgery
Heribert Schunkert |German Heart Center of Munich, Munich, Germany


Sebastian Kufner | Deutsches Herzzentrum Munich, Munich, Germany

Ten-Year Clinical Outcomes After Coronary Drug-Eluting Stents With Biodegradable or Permanent Polymer Coating: Results From the Randomized ISAR-TEST 4 Trial
Sebastian Kufner | Deutsches Herzzentrum Munich, Munich, Germany


Francis D Pagani | University of Michigan, Ann Arbor, MI

Intramyocardial Injection of Mesenchymal Precursor Cells in Left Ventricular Assist Device Recipients: Impact on Myocardial Recovery and Morbidity
Francis D Pagani | University of Michigan, Ann Arbor, MI